Ginkgo biloba Extracts: A Review of the Pharmacokinetics of the Active Ingredients
- 24 May 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 52 (9), 727-749
- https://doi.org/10.1007/s40262-013-0074-5
Abstract
Ginkgo biloba is among the most favourite and best explored herbal drugs. Standardized extracts of Ginkgo biloba represent the only herbal alternative to synthetic antidementia drugs in the therapy of cognitive decline and Alzheimer’s diseases. The clinical efficiency of such standardized Ginkgo biloba extracts (GBE) is still controversial, but authors of numerous international clinical studies recommended the use of GBE in the described therapies. Extracts of Ginkgo biloba are a mixture of substances with a wide variety of physical and chemical properties and activities. Numerous pharmacological investigations lead to the conclusion that the terpene trilactones (TTL) and the flavonoids of GBE are responsible for the main pharmacological effects of the extract in the therapy of cognitive decline. Therefore, the quality of GBE products must be oriented on a defined quantity of TTL and flavonoids. Furthermore, because of their toxic potential the amount of ginkgolic acid should be less than 5 ppm. However, data on pharmacokinetics and bioavailability, especially related to the central nervous system (CNS), which is the target tissue, are relatively rare. A few investigations characterize the TTL and flavonoids of Ginkgo biloba pharmacokinetically in plasma and in the brain. Recent investigations show that significant levels of TTL and Ginkgo biloba flavonoids cross the blood–brain barrier and enter the CNS of rats after oral application of GBE. Knowledge about the pharmacokinetic behaviour of these substances is necessary to discuss the pharmacological results on a more realistic basis.Keywords
This publication has 155 references indexed in Scilit:
- Improvement of auditory discrimination learning by Ginkgo biloba extract EGb 761®Neuroscience Letters, 2009
- Ginkgo biloba for cognitive impairment and dementiaCochrane Database of Systematic Reviews, 2009
- LAU-0901, a novel platelet-activating factor antagonist, is highly neuroprotective in cerebral ischemiaExperimental Neurology, 2008
- Ginkgo biloba for Prevention of DementiaA Randomized Controlled TrialJAMA, 2008
- Phylogeography of a living fossil: Pleistocene glaciations forced Ginkgo biloba L. (Ginkgoaceae) into two refuge areas in China with limited subsequent postglacial expansionMolecular Phylogenetics and Evolution, 2008
- Epigallocatechin-3-Gallate Enhances CD8+ T Cell–Mediated Antitumor Immunity Induced by DNA VaccinationCancer Research, 2007
- Role of GABAergic antagonism in the neuroprotective effects of bilobalideBrain Research, 2006
- LC–MS characterization of terpene lactones in plasma of experimental animals treated with Ginkgo biloba extracts: Correlation with pharmacological activityJournal of Pharmaceutical and Biomedical Analysis, 2006
- Lipid signaling: Sleep, synaptic plasticity, and neuroprotectionProstaglandins & Other Lipid Mediators, 2005
- Pharmacokinetics and Bioavailability of Quercetin Glycosides in HumansThe Journal of Clinical Pharmacology, 2001